Most Read

In the study, PPC-06 met both co-primary endpoints i.e. PASI-75 and IGA scores of 0 or 1 with at least a 2-point reduction from baseline, after 24 weeks

“We are thrilled to be advancing this strategic alliance with Janssen R&D for connecting biological information to disease condition and therapeutic mechanisms. By pairing the unique data science

The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetic profile of GFB-887 in healthy volunteers and in patients with chronic kidney disease. Topline safety data from

The trial is a multi-center, open-label, and multi-dose Phase Ib/II study that aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor efficacy of the combination in advanced

The results were presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The results from the trial showed a statistically-significant and

The objective of this study is to determine the effect of lenzilumab on the safety of Yescarta. Kite will act as the sponsor of this study and will

It will bring together Gubra’s established expertise in the design, synthesis, pharmaceutical characterization and in vivo testing of therapeutic peptides with Boehringer Ingelheim’s expertise in the research and

KCNQ2-NEE, a rare infant genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and profound developmental delay. The preclinical data were

Inheris will be responsible for launch preparation and commercialization for NKTR-181, a novel, first-in-class, investigational opioid molecule. NKTR-181 is currently under review with the U.S. Food and Drug